Seeking Alpha

Galectin prepares for secondary offering

  • Galectin Therapeutics (GALT) files an S-3 for a $100M secondary offering of common stock plus 500,000 shares of common registered for sale by Richard Uihlein.
  • The offering includes a sales agreement with MLV & Co. for up to $30M of potential time-to-time future sales.
This was corrected on 03/24/2014 at 02:42 PM.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: